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Abstract The recent discovery that an additional estrogen 
receptor (ER) subtype is present in various rat, mouse and human 
tissues has advanced our understanding of the mechanisms 
underlying estrogen signalling. The discovery of a second ER 
subtype (ER/J) suggests the existence of two previously 
unrecognised pathways of estrogen signalling: via the ER/} 
subtype in tissues exclusively expressing this subtype and via the 
formation of heterodimers in tissues expressing both ER 
subtypes. Various models have been suggested as explanations 
for the striking cell- and promoter-specific effects of estrogens 
and anti-estrogens, all on the basis of the assumption that only a 
single ER gene exists. This minireview describes several of these 
models and focuses on the potential role which the novel ER/J 
subtype might have in this regard. 
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1. Estrogens: mechanism of action 
The steroid hormone estrogen influences the growth, differ-
entiation and functioning of many target tissues. These in-
clude tissues of the male and female reproductive systems, 
such as mammary gland, uterus, vagina, ovary, testis, epidi-
dymis and prostate [1]. Estrogens also play an important role 
in bone maintenance, and in the cardiovascular system where 
estrogens have certain cardioprotective effects [2,3]. Estrogens 
are mainly produced in the ovaries and testis. They diffuse in 
and out of cells, but are retained with high affinity and spe-
cificity in target cells by an intranuclear binding protein, 
termed the estrogen receptor (ER). Once bound by estrogens, 
the ER undergoes a conformational change allowing the re-
ceptor to interact with high affinity with chromatin and to 
modulate transcription of target genes [4-6]. The ER is a 
member of the nuclear receptor superfamily of genes which 
consists of a surprisingly large number of genes [6]. It includes 
receptors for the steroids estrogen, progesterone, cortisol, al-
dosterone and testosterone. In addition it also includes recep-
tors for thyroid hormone, vitamin D, retinoic acids and ecdy-
sone. Cloning by various means has identified a large number 
of previously unknown genes having extensive sequence ho-
mology to the steroid/thyroid/retinoic acid receptor family [7]. 
For several of these so-called 'orphan receptors', which are 
putative receptors interacting with unknown compounds, li-
gands or activators have recently been identified [8,9]. Bio-
*Corresponding author. Fax: (46) 8-7745538. 
E-mail: george.kuiper@cbt.ki.se 
chemical and mutational analysis of estrogen receptors and 
other nuclear receptors indicated that they can be subdivided 
into several functional domains (Fig. 1) ([1,6] and references 
therein). The N-terminal A/B domain is highly variable in 
sequence and length, and usually contains a transactivation 
function, which activates target genes by interacting with 
components of the core transcriptional machinery ([10] and 
references therein). The C domain contains two type II zinc 
fingers, which are involved in specific DNA-binding and re-
ceptor dimerization. The ligand-binding domain is relatively 
large and is functionally complex. It does not only harbour 
regions important for ligand binding but also regions involved 
in receptor dimerization, nuclear localization and interactions 
with transcriptional co-activators and co-repressors [6,10]. 
The ER-encoding cDNAs were cloned during 1986 from 
several species [11-15]. Since that time there has been the 
general acceptance that only one ER gene existed, as is also 
accepted for the other steroid hormone receptors. This con-
trasts with other members of the nuclear receptor superfamily 
where multiple receptor subtypes have been identified, for in-
stance for thyroid hormones and retinoic acids [6]. The pro-
posed existence of only a single ER gene was also surprising in 
view of the striking differences in biocharacter that some syn-
thetic estrogens, anti-estrogens and their analogs show in 
terms of certain responses in different target cells and tissues 
[16]. 
2. Cloning and characterisation of ER/J 
At the end of 1995 a novel estrogen receptor (ER|3) was 
cloned from a rat prostate cDNA library [17]. The ER(3 sub-
type protein is highly homologous to the sofar known estro-
gen receptor protein (consequently ERa), particularly in the 
DNA-binding domain and in the ligand-binding domain (Fig. 
1). Saturation ligand-binding experiments reveal high affinity 
and specific binding of estradiol and the ER|3 protein is able 
to stimulate the transcription of an estrogen receptor target 
gene in an estradiol-dependent manner [17,18]. Some synthetic 
or naturally occuring ligands have different relative affinities 
for ERa vs ER[3, although many ligands (including various 
anti-estrogens) bind with very similar affinities to both ER 
subtypes [18]. The rat tissue distribution and/or the relative 
level of ERa and ERfS-mRNA expression is quite different; 
that is moderate to high expression in uterus, testis, pituitary, 
ovary, kidney, epididymis, adrenal for ERa and prostate, 
ovary, lung, bladder, brain, testis for ER[5 [18]. Examination 
of ER[3 mRNA expression at the cellular level, by in situ 
hybridisation, shows that in the rat prostate ER[3 is highly 
expressed in the epithelial cells of the secretory alveoli, where-
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as in the ovary the granulosa cells of primary, secondary and 
preovulatory follicles show expression of ER(3 [17,19]. In con-
trast, examination of ERa expression in the ovary reveals 
expression at a low level throughout the ovary with no partic-
ular cellular localization [19]. Additional experiments with im-
mature rats undergoing exogenous hormonal challenges dem-
onstrate that the preovulatory luteinizing hormone surge 
down-regulates ER(3-mRNA in the ovary [19]. These results 
clearly implicate the physiological importance of ER(3 in fe-
male reproductive functions. In rat brain ER(3 appears to 
represent a significant fraction of ER RNA [18], and exami-
nation of ERp mRNA expression by in situ hybridisation 
shows expression within various regions of the hypothalamus 
[20]. The mouse [21] and human [22] homologs of rat ER[3 
have been cloned in the meantime, and high expression in 
ovary and testis among other tissues was reported. 
None of the reports published sofar have compared ERa 
and ERp expression in different tissues at the protein level. 
The development of specific ERp antibodies and specific ERa 
antibodies is of great importance for the analysis of the pro-
tein expression pattern, needed also to confirm that the RNA 
levels of both subtypes parallel their protein expression level. 
3. ERj3 in the ERa knock-out mouse 
Knock-out mice in which the ERP gene has been disrup-
tedwould be very informative in elucidating the unique endo-
crine and physiological functions of ERp. These mice are not 
yet available, but in the meantime a lot can be learned from 
the ERa knock-out mice. Homozygous mutant mice with the 
ERa gene disrupted [23] were made at the time when it was 
thought that only a single ER gene exists. These mice appear 
healthy, and with the exception of fertility problems in male 
as well as female animals, there are no obvious problems in 
pre-natal sexual development [23,24]. This was quite surpris-
ing because of the known importance of estrogens in breast 
and uterine development and in preventing bone loss after 
menopause and after ovariectomy in mice [1,3,5]. Further-
more, the presence of ER in pre-implantation mouse embryos, 
and the absence of reported human ER mutations have been 
interpreted as indications for an essential role of estrogens 
during embryonic development [25]. This view was challenged 
not only by the survival of the ERa knock-out mice but also 
by the rather recent discovery of a male with (partial) estrogen 
190 256 360 554 600 
A/B DBD Hinge LBD F rERa 
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16.5 95.5 28.9 59.7 16.7 rERP 
Fig. 1. Comparison between rat ERa and ERp protein. Percentage 
amino-acid identity in the domains A/B (N-terminus), DBD/C 
(DNA-binding), hinge and LBD/F (ligand binding, dimerization and 
ligand-dependent transactivation) are depicted. Similar homologies 
are present in the respective domains of the human and mouse ER 
subtypes. 
Alternative 
Estrogen 
Signalling 
Pathways 
Fig. 2. Alternative estrogen signalling pathways. The existence of 
two ER subtypes and their ability to form DNA-binding hetero-
dimers, suggests the existence of three potential pathways of estro-
gen signalling. In cells expressing only the ERa or ERP subtype, 
homodimers of either subtype can interact with response elements in 
target genes promoters and influence transcription levels. In cells ex-
pressing both subtypes, heterodimers can be formed depending on 
the ratio of the subtypes. It cannot be excluded at this stage that 
unique response elements exist within the context of target gene 
promoters which interact preferentially with ERP homodimers or 
ERa/ERP heterodimers. An open question in this regard is whether 
estrogen target genes exist which are exclusively regulated by either 
of the homodimers or the heterodimer. 
resistance caused by a mutation in the ERa gene [26]. With 
the discovery of the ERP subtype, the unexpected viability of 
the ERa knock-out mouse and human with non-functional 
ERa protein, could also be explained by complementation 
through ERP protein during embryonal development. On 
the other hand the existence of a karyotypically female patient 
with pseudohermaphroditism caused by a null mutation in the 
aromatase cytochrome P-450 gene [27], the enzyme which is 
essential for estradiol biosynthesis, raises further questions 
about the exact role of estrogens and ER proteins during 
embryonal development. 
To what extent the lack of a phenotype in the breast, bone 
and cardiovascular tissue of the ERa knock-out mouse is due 
to up-regulation and compensation by ERP protein, or is a 
reflection of the normal physiological role of ERp is unknown 
at the moment. Although no data on the expression level of 
ERP-mRNA and protein in the ERa knock-out mouse has 
been published, it is clear that the presence of ERp protein 
should be kept in mind when interpreting experiments using 
the ERa knock-out mice. 
4. Tissue-specific effects of ER agonists and antagonists and 
potential role of ER/3 
It has been known for long that human breast cancers are 
hormone-dependent (i.e. estrogen- and progesterone-depend-
ent) and that they undergo regression when deprived of these 
supporting hormones by ovariectomy or hypophysectomy [5]. 
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With the development of anti-estrogens as tamoxifen, and 
derivatives thereof, an alternative to endocrine ablation be-
came available for the palliative treatment of hormone-de-
pendent breast cancer ([5] and references therein). Anti-estro-
gens bind with high affinity to the ER, but thereafter their 
effects differ from those of the physiological ligand estrogen. 
Most anti-estrogens exhibit curious pharmacological behav-
iour; depending on the species, the tissue and the dose ad-
ministered they can act as either agonists and antagonists 
[5,16]. For example, tamoxifen therapy in post-menopausal 
women with breast cancer has shown estrogen-like actions 
on bone mineral density and lipoprotein levels as well as es-
trogen-like effects in the uterus, while in contrast tamoxifen 
inhibits the development and recurrence of breast tumors ([16] 
and references therein). Various explanations, until recently 
based on the assumption that only a single ER gene exists, 
have been suggested for this puzzling pharmacological behav-
iour of certain anti-estrogens: 
4.1. Co-activators and co-repressors 
Transfection of estrogen-responsive promoter-reporter con-
structs into different cells enables one to study the regulation 
of specific genes in different cellular backgrounds. Studies us-
ing different cell types in such assays have provided clear 
evidence that, as expected from the clinical data, cell back-
ground influences the ERcc-mediated transcriptional response 
to different estrogens and anti-estrogens [28]. In addition to 
contacting the basal transcriptional machinery directly, ster-
oid receptors inhibit or enhance transcription by recruiting 
an array of co-activator and co-repressor proteins to the tran-
scription initiation complex. These co-regulatory proteins, 
which are present in limiting amounts in the cell, are believed 
to be interposed between the steroid receptor and the basal 
transcriptional machinery. In the last two years not less than 
10 different co-activators and co-repressors that can interact 
with the ER have been described ([10] and references therein). 
Although, no study has yet addressed the exact physiological 
relevance of each individual interacting protein, it is possible 
that they constitute a factor in the cell type- and promoter-
specific action of ER agonists and antagonists. The ratio and 
concentration of co-activators and co-repressors could be dif-
ferent in various cell types. Depending on the ligand (agonist 
or antagonist) bound to the ER and the structure of the target 
gene promoter different sets of co-activators and co-repressors 
could be associated with the ER [10]. The observation that 
tamoxifen acts as an antagonist in the breast and as an ago-
nist in the uterus could be explained by assuming that the 
balance of ER bound interacting proteins shifts from excess 
co-repressor to excess co-activator in the different cells. 
4.2. Antagonist-specific binding sites 
An extra layer of complexity is added by the observation 
that in addition to competing for the estrogen-binding site, the 
anti-estrogen 4-hydroxytamoxifen reacts with a second bind-
ing site in the ER, which is not recognised by estrogen [5,29]. 
Differences in the relative affinities for the two putative bind-
ing sites have been suggested to provide a clue as to how 4-
hydroxy-tamoxifen can function as an agonist or antagonist in 
a concentration-dependent manner in breast cancer cells [30]. 
4.3. ER activation of target gene expression via AP-1 sites 
In the 'classical' estrogen response ER activates transcrip-
tion after binding to estrogen response elements in the pro-
moter region of estrogen-responsive genes. An alternative 
pathway has been reported in which the ER appears to be 
able to stimulate transcription from promoters that contain an 
AP-1 site, the cognate binding site for the transcription factors 
Jun and Fos, rather than an estrogen response element [31]. 
The detailed mechanism by which the ER stimulates tran-
scription in this AP-1 site-dependent pathway is unknown. 
It is believed to involve protein-protein rather than protein-
DNA interactions, since it is partly independent of the ER 
DNA-binding domain [32]. Interestingly, it was found that the 
anti-estrogen tamoxifen is a potent activator of ER-mediated 
induction of transiently transfected promoter reporter con-
structs regulated by AP-1 sites in cell lines of uterine origin, 
but not in cell lines of breast origin [32]. It thus parallels 
tamoxifen agonism in vivo. However, to what extent the stim-
ulation of uterine endometrial growth by tamoxifen is medi-
ated by AP-1 site-containing ER target gene promoters re-
mains to be investigated. 
4.4. Multiple ER subtypes 
The recent discovery that an additional estrogen receptor 
subtype (ERP) is present in various rat [18] mouse[21] and 
human [22] tissues has advanced significantly our understand-
ing of the mechanisms underlying estrogen signalling. It sug-
gests the existence of two previously unrecognised pathways 
of estrogen signalling; via ERp in cells exclusively expressing 
this subtype and via the formation of heterodimers in cells 
expressing both ER subtypes (Fig. 2). The ERP protein inter-
acts in vitro as a homodimer with similar estrogen response 
element (ERE) oligonucleotides as the ERoc protein, and in 
subsequent experiments it was shown that ERoc and ERP 
proteins form heterodimeric complexes with ERE oligonu-
cleotides (Pettersson et al., submitted). At the moment the 
possibility cannot be excluded that ERP homodimers interact 
with novel response elements, apart from the known EREs. 
The existence of two ER subtypes greatly expands the phys-
iological regulatory potential of estrogenic hormones. Differ-
ent target cells may respond differently to the same hormonal 
stimulus due to alternative composition of receptors. Varying 
ratios of ERa and ERp proteins in different cells, resulting in 
different populations of homo- and heterodimers could con-
stitute a hitherto unrecognised mechanism involved in the 
tissue- and cell type-specific actions of not only estrogens 
but also of anti-estrogens. The anti-estrogen 4-hydroxytamox-
ifen inhibits estradiol-stimulated transcriptional activity of 
ERa as well as of ERp. However, while 4-hydroxytamoxifen 
alone displays partial agonistic activity with mouse ERa on a 
basal promoter linked to ERE-elements in COS-1 cells, this 
effect is not observed with mouse ERp [21], showing that in-
deed the molecular mechanisms regulating the transcriptional 
activity of ERa and ERP can differ under appropiate condi-
tions. No data has yet been presented on the actions of estro-
gens and anti-estrogens in cells expressing both ER subtypes. 
5. Concluding remarks 
The described mechanisms, proposed to explain the tissue-
and cell-specific actions of estrogens and anti-estrogens, are by 
no means mutually excluding. The challenge for the future 
will be to unravel for each particular situation the relative 
importance of these mechanisms and to exploit this knowl-
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edge for the development of E R antagonists with improved [17 
therapeutic profiles. 
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